The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Exciting lymphoma updates to expect at ASH 2023
Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, comments on what she is most looking forward to in the space of lymphoma at the upcoming American Society of Hematology (ASH) 2023 meeting; namely the updates of trials such as EPCORE NHL-1 (NCT03625037) and hearing about long-term outcomes of studies for which preliminary data was presented at prior meetings. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie, AstraZeneca, Genmab, MEI Pharma, Genentech, Seattle Genetics, Lilly
